Company Profile
Fennec Pharmaceuticals Inc. Stock Price, News & Analysis
- Ticker:
- FENC
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Fennec Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
10.30 USD (+8.08%)
Close
Last updated: June 23, 2026 at 00:00
357.79M USD
Market cap
Why the stock is moving
FENC is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Fennec Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Fennec Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Fennec Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Fennec Announces Results of Annual Meeting
Source: Fennec Pharmaceuticals Inc.
- 02
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Source: Fennec Pharmaceuticals Inc.
- 03
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Fennec Pharmaceuticals Inc.
- 04
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Fennec Pharmaceuticals Inc.
- 05
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Source: Fennec Pharmaceuticals Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fennec Pharmaceuticals Inc. (FENC)?
Fennec Pharmaceuticals Inc. (FENC) most recently closed at 10.30 USD, a +8.08% move versus the previous session.
What is the market cap of Fennec Pharmaceuticals Inc. (FENC)?
Fennec Pharmaceuticals Inc. currently has a market capitalization of 357.79M USD on BioPharmSignal.
What does Fennec Pharmaceuticals Inc. do?
Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is FENC stock listed?
Fennec Pharmaceuticals Inc. (FENC) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Fennec Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Fennec?
Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Fennec Pharmaceuticals Inc. targeting with Fennec?
Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Pharmaceuticals?
Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.